ALNY logo

ALNY Alnylam Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$143.82
-4.00 (-2.71%)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic …

Market Cap: $19.26Bwww.alnylam.com

Price

No data yet.

Social Signal Score

53
5d
45
2 mentions
—
30d
59
21 mentions
—
60d
55
32 mentions
—
90d
54
42 mentions
—
news: 27 · rss: 11 · marketaux: 4

Analyst Ratings

52 analysts
Buyconsensus
Strong Buy 0Buy 37Hold 14Sell 1Strong Sell 0
Avg price target$326.73+127.2%
Low $225Median $315High $455
Current Consensus

Revenue

$1.46B+8253.88%
$2.07M$487.41M$972.75M$1.46B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$2.46
$1.39–$3.18
10 analysts
FY2026
$20.26+724% YoY
$8.94–$24.87
16 analysts
FY2027
$8.13-60% YoY
$6.59–$10.09
16 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Yvonne L. Greenstreet
Sector
Healthcare
Industry
Biotechnology
Employees
2,500
Beta
0.27
Country
US
Piotroski score
5 / 9 (Middling)
Altman Z-score
3.48
www.alnylam.com